exclusion of subject due to vomiting [Regulatives / Guidelines]

posted by ratnakar1811 – India, 2011-06-15 08:49 (5494 d 22:42 ago) – Posting: # 7128
Views: 11,525

Dear HS and Ohlbe,
Thanks for prompt reply;

❝ In my studies for EMA I’m using FDA’s rules (IR: 2× tmax,ref, MR: τ) and never had any problems.


Were there any queries from any of the regulatory authority from EU, after recent guideline has been implemented, as one of our sponsors is not very satisfied with the approach and asking to withdraw a subject from the study during clinical phase only if there is any vomiting during clinical phase?

Best Regards,

Ratnakar

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,571 registered users;
314 visitors (0 registered, 314 guests [including 15 identified bots]).
Forum time: 07:32 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5